Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

20151,107 citationsJournal Articlebronze Open Access

Authors

Henk M. Lokhorst · University Medical Center

Torben Plesner · University of Southern Denmark

Jacob P. Laubach · Harvard University

Hareth Nahi · Karolinska University Hospital

Peter Gimsing · Rigshospitalet

Markus Hansson · Lund University

Monique C. Minnema ·

Abstract

Daratumumab monotherapy had a favorable safety profile and encouraging efficacy in patients with heavily pretreated and refractory myeloma. (Funded by Janssen Research and Development and Genmab; ClinicalTrials.gov number, NCT00574288.).

Topics & Keywords

Multiple Myeloma Research and Treatments Peptidase Inhibition and Analysis Chronic Lymphocytic Leukemia Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 373, Issue 13, pp. 1207-1219

DOI: 10.1056/nejmoa1506348

Field-Weighted Citation Impact: 86.69